HR3008-118

Introduced

To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical essential medicines of increased demand of such drugs, and for other purposes.

118th Congress Introduced Apr 28, 2023

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

The bill provides improving notification procedures in case of increased demand for critical essential medicines Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. It relies on definition changes, appropriations, compliance mandates, and product standards. The main policy areas are Healthcare Consumers, Criminal Justice, Environment, and Healthcare.

Who Benefits and How

Telecommunications providers and users affected by the bill could face lower compliance burdens, Patients and health care consumers affected by the bill could face lower compliance burdens, and Environmental and public health interests affected by the bill could face lower compliance burdens.

Who Bears the Burden and How

Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.

Key Provisions

  • Provides improving notification procedures in case of increased demand for critical essential medicines Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

The bill provides improving notification procedures in case of increased demand for critical essential medicines Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Key Policy Areas

Healthcare Consumers, Criminal Justice, Environment, Healthcare

Primary Purpose

The bill provides improving notification procedures in case of increased demand for critical essential medicines Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Policy Domains

Healthcare Consumers Criminal Justice Environment Healthcare

Whole bill

Identified Gains
  • Telecommunications providers and users affected by the bill
  • Patients and health care consumers affected by the bill
  • Environmental and public health interests affected by the bill
  • Disaster response agencies and disaster-affected communities
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
Patients and health care consumers affected by the bill:
Telecommunications providers and users affected by the bill:
Disaster response agencies and disaster-affected communities:
Environmental and public health interests affected by the bill:
Identified Costs
  • Federal, state, or local agencies responsible for implementing the clause
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
Federal, state, or local agencies responsible for implementing the clause:

Legislative Progress

Introduced
Introduced Committee Passed
Apr 28, 2023

Ms. Jacobs (for herself, Mr. Allred, Ms. Clarke of New …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Consumers Criminal Justice Environment Healthcare

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology